enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Mycobacterium kansasii is a slow-growing, non-tuberculosis mycobacterium (NTM) that, like other mycobacterial species, tends to cause six clinical patterns of infection: pulmonary disease, skin and soft tissue disease, musculoskeletal infections including monoarticular septic arthritis and tenosynovitis, disseminated disease, catheter ...

  3. Mycobacterium kansasii - Wikipedia

    en.wikipedia.org/wiki/Mycobacterium_kansasii

    Mycobacterium kansasii is a bacterium in the Mycobacterium genus. It is an environmental bacteria that causes opportunistic infections in humans, and is one of the leading mycobacterial causes of human disease after tuberculosis and leprosy .

  4. Treatment of lung infection with Mycobacterium kansasii and ... -...

    www.uptodate.com/contents/treatment-of-lung-infection-with-mycobacterium...

    The treatment of lung infections due to M. kansasii and other non-MAC slow growing nontuberculous mycobacteria will be reviewed here. Management of pulmonary infections due to MAC and to rapidly growing mycobacterium (Mycobacterium abscessus, Mycobacterium fortuitum complex, and Mycobacterium chelonae) are discussed separately

  5. Mycobacterium Kansasii: Background, Pathophysiology, Epidemiology

    emedicine.medscape.com/article/223230-overview

    Mycobacterium kansasii is an acid-fast bacillus (AFB) that is readily recognized based on its characteristic photochromogenicity, which produces a yellow pigment when exposed to light. In...

  6. Therapy for Mycobacterium kansasii Infection: Beyond 2018

    pmc.ncbi.nlm.nih.gov/articles/PMC6166578

    The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity.

  7. Mycobacterium kansasii is one of the most virulent and prevalent NTM pathogen in human medicine. It was first described by Buhler and Pollak in 1953 from a series of respiratory samples of patients with a TB-like pulmonary disease (Buhler and Pollak, 1953).

  8. Mycobacterium kansasii - Microbiology Spectrum

    journals.asm.org/doi/10.1128/microbiolspec.tnmi7-0011-2016

    The incidence of Mycobacterium kansasii varies widely over time and by region, but this organism remains one of the most clinically relevant isolated species of nontuberculous mycobacteria.

  9. Clinical Characteristics and Treatment Outcomes of Mycobacterium...

    www.ncbi.nlm.nih.gov/pmc/articles/PMC2880268

    Mycobacterium kansasii is the second most common nontuberculous mycobacteria (NTM) after the Mycobacterium avium complex in the United States and Japan, 1, 2 and is the most common cause of NTM lung disease in the United Kingdom and Western Europe. 3, 4 Infection with M. kansasii probably occurs via an aerosol route.

  10. Clinical and Microbiological Characteristics of Mycobacterium...

    journals.asm.org/doi/10.1128/spectrum.01475-21

    Mycobacterium kansasii, an important opportunistic pathogen of humans, causes serious pulmonary disease. Sixty M. kansasii isolates were collected for investigating the clinical characteristics of patients with M. kansasii infections as well as drug susceptibility and genotypes of M. kansasii.

  11. Mycobacterium kansasii Infection - PubMed

    pubmed.ncbi.nlm.nih.gov/28613656

    Mycobacterium kansasii is a non-tuberculosis mycobacterium (NTM) that is readily recognized based on its characteristic photochromogenicity; it produces a yellow pigment when exposed to light. Buhler and Pollack first described this slow-growing mycobacterium in 1953. Under light microscopy, …